The evolving role of multimodal imaging, artificial intelligence and radiomics in the radiologic assessment of immune related adverse events Review
| Authors: | Das, J. P.; Ma, H. Y.; DeJong, D.; Prendergast, C.; Baniasadi, A.; Braumuller, B.; Giarratana, A.; Khonji, S.; Paily, J.; Shobeiri, P.; Yeh, R.; Dercle, L.; Capaccione, K. M. |
| Review Title: | The evolving role of multimodal imaging, artificial intelligence and radiomics in the radiologic assessment of immune related adverse events |
| Abstract: | Immunotherapy, in particular checkpoint blockade, has revolutionized the treatment of many advanced cancers. Imaging plays a critical role in assessing both treatment response and the development of immune toxicities. Both conventional imaging and molecular imaging techniques can be used to evaluate multisystemic immune related adverse events (irAEs), including thoracic, abdominal and neurologic irAEs. As artificial intelligence (AI) proliferates in medical imaging, radiologic assessment of irAEs will become more efficient, improving the diagnosis, prognosis, and management of patients affected by immune-related toxicities. This review addresses some of the advancements in medical imaging including the potential future role of radiomics in evaluating irAEs, which may facilitate clinical decision-making and improvements in patient care. © 2025 Elsevier B.V., All rights reserved. |
| Keywords: | treatment response; unclassified drug; major clinical study; review; bevacizumab; cisplatin; advanced cancer; side effect; solid tumor; capecitabine; nuclear magnetic resonance imaging; positron emission tomography; endometrium carcinoma; carboplatin; ipilimumab; melanoma; computer assisted tomography; breast cancer; image analysis; lung cancer; molecular imaging; diagnostic imaging; urogenital tract cancer; patient care; immunotherapy; systematic review; artificial intelligence; uterine cervix cancer; diagnosis; pancreatitis; medulloblastoma; fluorodeoxyglucose f 18; radiopharmaceutical agent; oropharynx cancer; colitis; radiography; nasopharynx carcinoma; liver cancer; ependymoma; clinical decision making; bile duct carcinoma; meningioma; choroid tumor; axitinib; toxicity; esophagus cancer; uterus cancer; decision making; neurologic disease; transitional cell carcinoma; sarcoidosis; adverse drug reaction; thorax disease; biliary tract cancer; pet/ct; immunotoxicity; pineal body tumor; enterocolitis; programmed death 1 ligand 1; clear cell renal cell carcinoma; non small cell lung cancer; abdominal disease; head and neck squamous cell carcinoma; gastrointestinal tumor; hypophysitis; differentiated thyroid cancer; adverse events; multimodal imaging; myocarditis; lung sarcoidosis; immune checkpoint inhibitor; cabozantinib; immunocytotoxicity; conventional imaging; nivolumab; mpdl 3280a; lenvatinib; human; metastatic castration resistant prostate cancer; pembrolizumab; atezolizumab; deep learning; radiomics; convolutional neural network; avelumab; positron emission tomography-computed tomography; camrelizumab; toripalimab; enfortumab vedotin; immune related adverse events; immune related adverse event; radiomic; tislelizumab; catequentinib; penpulimab; generative pretrained transformer; central nervous system vasculitis; immune toxicities; avelumab zr 89; df ab2m zr 89; df iab 22m2c zr 89; dfo atezolizumab zr 89; dfo daratumumab zr 89; dfo regn 3504 zr 89; dfo ys5 zr 89; ed 88082a zr 89; ht84 66 m5a dota cu 64; mpdl 3280a zr 89; trastuzumab zr 89; checkpoint inhibitor pneumonitis; transverse myelitis |
| Journal Title: | Clinical Imaging |
| Volume: | 125 |
| ISSN: | 0899-7071 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-09-01 |
| Start Page: | 110571 |
| Language: | English |
| DOI: | 10.1016/j.clinimag.2025.110571 |
| PUBMED: | 40743785 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work